Von Hippel-Lindau disease

Lancet

Volumn 361, Issue 9374, 2003, Pages 2059-2067

  Lonser, Russell R ^a   Glenn, Gladys M ^b   Walther, McClellan ^b   Chew, Emily Y ^c   Libutti, Steven K ^b   Linehan, W Marston ^b   Oldfield, Edward H ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; METIROSINE; VASCULOTROPIN ANTIBODY;

ADRENAL CYST; ADRENAL TUMOR; AUTOSOMAL DOMINANT INHERITANCE; BENIGN TUMOR; BROAD LIGAMENT; CANCER; CANCER SURGERY; CENTRAL NERVOUS SYSTEM TUMOR; CHROMOSOME 3; CHROMOSOME ARM; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CRYOTHERAPY; CYSTADENOMA; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DNA SEQUENCE; ECHOGRAPHY; ENDOLYMPHATIC SAC; EPIDIDYMIS; GENE MUTATION; GENETIC PROCEDURES; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; HEMANGIOBLASTOMA; HERITABILITY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY TUMOR; LASER COAGULATION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; PANCREAS TUMOR; PATIENT CARE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RADIOFREQUENCY RADIATION; RETINA TUMOR; SCREENING TEST; SOUTHERN BLOTTING; SYMPTOM; SYNDROME; TREATMENT INDICATION; TUMOR DIAGNOSIS; TUMOR SUPPRESSOR GENE; VISUAL IMPAIRMENT; VITRECTOMY; VON HIPPEL LINDAU DISEASE;

EID: 0037709883     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13643-4     Document Type: Conference Paper

References (98)

1. Linehan W.M., Zbar B., Klausner R. Renal carcinoma. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The metabolic and molecular basis of inherited disease. 8th edn:2001;907-929 McGraw-Hill, New York.
2. Linehan W.M., Zbar B., Klausner R. Renal Carcinoma. Vogelstein B., Kinzler K. The genetic basis of human cancer. 2 edn:2002;McGraw-Hill, New York.
3. Linehan W.M., Lerman M.I., Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA. 273:1995;564-570.
4. Clifford S.C., Maher E.R. Von Hippel-Lindau disease: clinical and molecular perspectives. Adv Cancer Res. 82:2001;85-105.
5. Maher E.R., Kaelin W.G. Jr. von Hippel-Lindau disease. Medicine (Baltimore). 76:1997;381-391.
6. Kaelin W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2:2002;673-682.
7. Maddock I.R., Moran A., Maher E.R., et al. A genetic register for von Hippel-Lindau disease. J Med Genet. 33:1996;120-127.
8. Richard S., Campello C., Taillandier L., Parker F., Resche F. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL Study Group. J Intern Med. 243:1998;547-553.
9. Lamiell J.M., Salazar F.G., Hsia Y.E. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine. 68:1989;1-29.
10. Lonser R.R., Weil R.J., Wanebo J.E., DeVroom H.L., Oldfield E.H. Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg. 98:2003;106-116.
11. Wanebo J.E., Lonser R.R., Glenn G.M., Oldfield E.H. The natural history of central nervous system hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg. 98:2003;82-94.
12. Weil R.J., Lonser R.R., DeVroom H.L., Wanebo J., Oldfield E.H. Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg. 98:2003;95-105.
13. Dollfus H., Massin P., Taupin P., et al. Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophthalmol Vis Sci. 43:2002;3067-3074.
14. Webster A.R., Maher E.R., Moore A.T. Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch Ophthalmol. 117:1999;371-378.
15. Hammel P.R., Vilgrain V., Terris B., et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology. 119:2000;1087-1095.
16. Richard S., David P., Marsot-Dupuch K., Giraud S., Beroud C., Resche F. Central nervous system hemangioblastomas, endolymphatic sac tumours, and von Hippel-Lindau disease. Neurosurg Rev. 23:2000;1-22. discussion 23-24.
17. Friedrich C.A. Von Hippel-Lindau syndrome: a pleomorphic condition. Cancer. 86:(suppl):1999;2478-2482.
18. Maher E.R., Iselius L., Yates J.R., et al. Von Hippel-Lindau disease: a genetic study. J Med Genet. 28:1991;443-447.
19. Neumann H.P., Wiestler O.D. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet. 337:1991;1052-1054.
20. Maher E.R., Yates J.R., Harries R., et al. Clinical features and natural history of von Hippel-Lindau disease. QJM. 77:1990;1151-1163.
21. Neumann H.P., Eggert H.R., Scheremet R., et al. Central nervous system lesions in von Hippel-Lindau syndrome. J Neurol Neurosurg Psychiatry. 55:1992;898-901.
22. Choyke P.L., Glenn G.M., Walther M.M., Patronas N.J., Linehan W.M., Zbar B. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology. 194:1995;629-642.
23. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumour suppressor gene. Science. 260:1993;1317-1320.
24. Knudson A.G.J., Strong L.C. Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet. 24:1972;514-532.
25. Knudson A.G.J. Genetics of human cancer. Ann Rev Genet. 20:1986;231-251.
26. Kanno H., Kondo K., Ito S., et al. Somatic mutations of the von Hippel-Lindau tumour suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res. 54:1994;4845-4847.
27. Lee J.Y., Dong S.M., Park W.S., et al. Loss of heterozygosity and somatic mutations of the VHL tumour suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res. 58:1998;504-508.
28. Oberstrass J., Reifenberger G., Reifenberger J., Wechsler W., Collins V.P. Mutation of the Von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system. J Pathol. 179:1996;151-156.
29. Tse J.Y., Wong J.H., Lo K.W., Poon W.S., Huang D.P., Ng H.K. Molecular genetic analysis of the von Hippel-Lindau disease tumour suppressor gene in familial and sporadic cerebellar hemangioblastomas. Am J Clin Pathol. 107:1997;459-466.
30. Gnarra J.R., Tory K., Weng Y., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 7:1994;85-90.
31. Brieger J., Weidt E.J., Schirmacher P., Storkel S., Huber C., Decker H.J. Inverse regulation of vascular endothelial growth factor and VHL tumour suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumours. J Mol Med. 77:1999;505-510.
32. Gallou C., Joly D., Mejean A., et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum Mutat. 13:1999;464-475.
33. Kondo K., Yao M., Yoshida M., et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer. 34:2002;58-68.
34. Lee S., Chen D.Y., Humphrey J.S., Gnarra J.R., Linehan W.M., Klausner R.D. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumour suppressor gene product is determined by cell density. Proc Natl Acad Sci USA. 93:1996;1770-1775.
35. Ohh M., Kaelin W.G. Jr. The von Hippel-Lindau tumour suppressor protein: new perspectives. Mol Med Today. 5:1999;257-263.
36. Duan D.R., Pause A., Burgess W.H., et al. Inhibition of transcription elongation by the VHL tumour suppressor protein. Science. 269:1995;1402-1406.
37. Pause A., Lee S., Worrell R.A., et al. The von Hippel-Lindau tumour-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA. 94:1997;2156-2161.
38. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275.
39. Bohling T., Hatva E., Kujala M., Claesson-Welsh L., Alitalo K., Haltia M. Expression of growth factors and growth factor receptors in capillary hemangioblastoma. J Neuropathol Exp Neurol. 55:1996;522-527.
40. Reifenberger G., Reifenberger J., Bilzer T., Wechsler W., Collins V.P. Coexpression of transforming growth factor-alpha and epidermal growth factor receptor in capillary hemangioblastomas of the central nervous system. Am J Pathol. 147:1995;245-250.
41. Carmeliet P., Dor Y., Herbert J.M., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:1998;485-490.
42. Ohh M., Yauch R.L., Lonergan K.M., et al. The von Hippel-Lindau tumour suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell. 1:1998;959-968.
43. Pause A., Lee S., Lonergan K.M., Klausner R.D. The von Hippel-Lindau tumour suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA. 95:1998;993-998.
44. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., Klausner R.D. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 1:2002;247-255.
45. Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Jr. Inhibition of HIF is necessary for tumour suppression by the von Hippel-Lindau protein. Cancer Cell. 1:2002;237-246.
46. Seagroves T., Johnson R.S. Two HIFs may be better than one. Cancer Cell. 1:2002;211-213.
47. Gnarra J.R., Zhou S., Merrill M.J., et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumour suppressor gene. Proc Natl Acad Sci USA. 93:1996;10589-10594.
48. Mukhopadhyay D., Knebelmann B., Cohen H.T., Ananth S., Sukhatme V.P. The von Hippel-Lindau tumour suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol. 17:1997;5629-5639.
49. Escourolle R., Poirer J. Manual of Neuropathology. 2nd edn:1978;49-51 WB Saunders, Philadelphia.
50. Melmon K.L., Rosen S.W. Lindau's disease. Am J Med. 36:1964;595-617.
51. Zbar B., Kishida T., Chen F., et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat. 8:1996;348-357.
52. Clifford S.C., Cockman M.E., Smallwood A.C., Mole D.R., Woodward E.R. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet. 10:2001;1029-1038.
53. Chen F., Kishida T., Yao M., et al. Germline mutations in the von Hippel-Lindau disease tumour suppressor gene: correlations with phenotype. Hum Mutat. 5:1995;66-75.
54. Brauch H., Kishida T., Glavac D., et al. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet. 95:1995;551-556.
55. Cybulski C., Krzystolik K., Murgia A., et al. Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene. J Med Genet. 39:2002;E38.
56. Hes F., Zewald R., Peeters T., et al. Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. Hum Genet. 106:2000;425-431.
57. Stolle C., Glenn G., Zbar B., et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumour suppressor gene. Hum Mutat. 12:1998;417-423.
58. Sgambati M.T., Stolle C., Choyke P.L., et al. Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet. 66:2000;84-91.
59. Filling-Katz M.R., Choyke P.L., Oldfield E., et al. Central nervous system involvement in Von Hippel-Lindau disease. Neurology. 41:1991;41-46.
60. Berkman R.A., Merrill M.J., Reinhold W.C., et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest. 91:1993;153-159.
61. Vortmeyer A.O., Gnarra J.R., Emmert-Buck M.R., et al. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol. 28:1997;540-543.
62. Malis L.I. Atraumatic bloodless removal of intramedullary hemangioblastomas of the spinal cord. J Neurosurg. 97:(suppl 1):2002;1-6.
63. Chandler H.C. Jr, Friedman W.A. Radiosurgical treatment of a hemangioblastoma: case report. Neurosurgery. 34:1994;353-355.
64. Chakraborti P.R., Chakrabarti K.B., Doughty D., Plowman P.N. Stereotactic multiple are radiotherapy. IV-Haemangioblastoma. Br J Neurosurg. 11:1997;110-115.
65. Niemela M., Lim Y.J., Soderman M., Jaaskelainen J., Lindquist C. Gamma knife radiosurgery in 11 hemangioblastomas. J Neurosurg. 85:1996;591-596.
66. Page K.A., Wayson K., Steinberg G.K., Adler J.R. Jr. Stereotaxic radiosurgical ablation: an alternative treatment for recurrent and multifocal hemangioblastomas: a report of four cases. Surg Neurol. 40:1993;424-428.
67. Patrice S.J., Sneed P.K., Flickinger J.C., et al. Radiosurgery for hemangioblastoma: results of a multiinstitutional experience. Int J Radiat Oncol Biol Phys. 35:1996;493-499.
68. Chang S.D., Meisel J.A., Hancock S.L., Martin D.P., McManus M., Adler J.R. Jr. Treatment of hemangioblastomas in von Hippel-Lindau disease with linear accelerator-based radiosurgery. Neurosurgery. 43:1998;28-34.
69. Chan C.C., Vortmeyer A.O., Chew E.Y., et al. VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Arch Ophthalmol. 117:1999;625-630.
70. Singh A.D., Nouri M., Shields C.L., Shields J.A., Perez N. Treatment of retinal capillary hemangioma. Ophthalmology. 109:2002;1799-1806.
71. Aiello L.P., George D.J., Cahill M.T., et al. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology. 109:2002;1745-1751.
72. Manski T.J., Heffner D.K., Glenn G.M., et al. Endolymphatic sac tumours: a source of morbid hearing loss in von Hippel-Lindau disease. JAMA. 277:1997;1461-1466.
73. Poston C.D., Jaffe G.S., Lubensky I.A., et al. Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol. 153:1995;22-26.
74. Walther M.M., Choyke P.L., Glenn G., et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumour size threshold for renal parenchymal sparing surgery. J Urol. 161:1999;1475-1479.
75. Walther M.M., Lubensky I.A., Venzon D., Zbar B., Linehan W.M. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol. 154:1995;2010-2014.
76. Choyke P.L., Glenn G.M., Walther M.M., et al. The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR Am J Roentgenol. 159:1992;1229-1234.
77. Pavlovich C.P., Walther M.M., Choyke P.L., et al. Percutaneous radio frequency ablation of small renal tumours: initial results. J Urol. 167:2002;10-15.
78. Shingleton W.B., Sewell P.E. Jr. Percutaneous renal tumour cryoablation with magnetic resonance imaging guidance. J Urol. 165:2001;773-776.
79. Shingleton W.B., Sewell P.E. Jr. Percutaneous renal cryoablation of renal tumours in patients with von Hippel-Lindau disease. J Urol. 167:2002;1268-1270.
80. Walther M.M., Reiter R., Keiser H.R., et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol. 162:1999;659-664.
81. Eisenhofer G., Lenders J.W., Linehan W.M., Walther M.M., Goldstein D.S., Keiser H.R. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med. 340:1999;1872-1879.
82. Weise M., Merke D.P., Pacak K., Walther M.M., Eisenhofer G. Utility of plasma free metanephrines for detecting childhood pheochromocytoma. J Clin Endocrinol Metab. 87:2002;1955-1960.
83. Pavlovich C.P., Linehan W.M., Walther M.M. Partial adrenalectomy in patients with multiple adrenal tumours. Curr Urol Rep. 2:2001;19-23.
84. Baghai M., Thompson G.B., Young W.F. Jr, Grant C.S., Michels V.V., van Heerden J.A. Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: a role for laparoscopic and cortical-sparing surgery. Arch Surg. 137:2002;682-688.
85. Libutti S.K., Choyke P.L., Bartlett D.L., et al. Pancreatic neuroendocrine tumours associated with von Hippel-Lindau disease: diagnostic and management recommendations. Surgery. 124:1998;1153-1159.
86. Binkovitz L.A., Johnson C.D., Stephens D.H. Islet cell tumours in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. AJR Am J Roentgenol. 155:1990;501-505.
87. Lubensky I.A., Pack S., Ault D., et al. Multiple neuroendocrine tumours of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol. 153:1998;223-231.
88. Neumann H.P., Dinkel E., Brambs H., et al. Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology. 101:1991;465-471.
89. Hough D.M., Stephens D.H., Johnson C.D., Binkovitz L.A. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. AJR Am J Roentgenol. 162:1994;1091-1094.
90. Libutti S.K., Choyke P.L., Alexander H.R., et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumours associated with von Hippel-Lindau disease. Surgery. 128:2000;1022-1027.
91. Gruber M.B., Healey G.B., Toguri A.G., Warren M.M. Papillary cystadenoma of epididymis: component of von Hippel-Lindau syndrome. Urology. 16:1980;305-306.
92. Lissens P., Michiels H., Geysens P., Van de Voorde W., Lauweryns J. Papillary cystadenoma of the epididymis: a case report. Acta Urol Belg. 63:1995;109-112.
93. Wernert N., Goebbels R., Prediger L. Papillary cystadenoma of the epididymis: case report and review of the literature. Pathol Res Pract. 181:1986;260-264.
94. Billesbolle P., Nielsen K. Papillary cystadenoma of the epididymis. J Urol. 139:1988;1062.
95. Choyke P.L., Glenn G.M., Wagner J.P., et al. Epididymal cystadenomas in von Hippel-Lindau disease. Urology. 49:1997;926-931.
96. Funk K.C., Heiken J.P. Papillary cystadenoma of the broad ligament in a patient with von Hippel-Lindau disease. AJR Am J Roentgenol. 153:1989;527-558.
97. Gaffey M.J., Mills S.E., Boyd J.C. Aggressive papillary tumour of middle ear/temporal bone and adnexal papillary cystadenoma. Manifestations of von Hippel-Lindau disease. Am J Surg Pathol. 18:1994;1254-1260.
98. Gersell D.J., King T.C. Papillary cystadenoma of the mesosalpinx in von Hippel-Lindau disease. Am J Surg Pathol. 12:1988;145-149.